{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:32:34Z","timestamp":1781530354327,"version":"3.54.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and survival rates have barely improved in decades. In the era of precision medicine, treatment strategies tailored to disease mutations have revolutionized cancer therapy. Next generation sequencing has found that up to a third of all PDAC tumors contain deleterious mutations in DNA damage repair (DDR) genes, highlighting the importance of these genes in PDAC. The mechanisms by which DDR gene mutations promote tumorigenesis, therapeutic response, and subsequent resistance are still not fully understood. Therefore, an opportunity exists to elucidate these processes and to uncover relevant therapeutic drug combinations and strategies to target DDR deficiency in PDAC. However, a constraint to preclinical research is due to limitations in appropriate laboratory experimental models. Models that effectively recapitulate their original cancer tend to provide high levels of predictivity and effective translation of preclinical findings to the clinic. In this review, we outline the occurrence and role of DDR deficiency in PDAC and provide an overview of clinical trials that target these pathways and the preclinical models such as 2D cell lines, 3D organoids and mouse models [genetically engineered mouse model (GEMM), and patient-derived xenograft (PDX)] used in PDAC DDR deficiency research.<\/jats:p>","DOI":"10.3389\/fcell.2021.749490","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:46:57Z","timestamp":1634147217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives"],"prefix":"10.3389","volume":"9","author":[{"given":"Jojanneke","family":"Stoof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Harrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mariottino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve A.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"B1","first-page":"S3","article-title":"Current treatment landscape and emerging therapies for pancreatic cancer.","volume":"25","author":"Adel","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer.","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2015.04.003","article-title":"Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1\/2 inhibitor BMN 673.","volume":"364","author":"Andrei","year":"2015","journal-title":"Cancer Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pan.2019.11.006","article-title":"Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.","volume":"20","author":"Ariston Gabriel","year":"2020","journal-title":"Pancreatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-43","article-title":"Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.","volume":"7","author":"Azorsa","year":"2009","journal-title":"J. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer.","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer.","volume":"26","author":"Bendell","year":"2015","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.22852","article-title":"Validation of the 6th edition AJCC pancreatic cancer staging system.","volume":"110","author":"Bilimoria","year":"2007","journal-title":"Cancer"},{"key":"B10","first-page":"2813","article-title":"Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.","volume":"10","author":"Chen","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.4014","article-title":"Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.","volume":"37","author":"Chiorean","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.28.013763","article-title":"Evaluating the sensitivity of sporadic pancreatic cancer to poly(ADP-ribose) polymerase (PARP) inhibition (Velaparib, Olaparib, AG14361) as single agents and as chemo-sensitizers.","author":"de Soto","year":"2020","journal-title":"bioRxiv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer.","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines.","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","article-title":"Models and technologies modeling therapy resistance in BRCA1\/2-mutant cancers.","volume":"16","author":"Dr\u00e9an","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.gastro.2020.09.043","article-title":"Targeting DNA damage response and replication stress in pancreatic cancer.","volume":"160","author":"Dreyer","year":"2021","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","article-title":"Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.","volume":"116","author":"Driehuis","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11661-8","article-title":"ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.","volume":"7","author":"Drosos","year":"2017","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1073\/PNAS.1812410116","article-title":"Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion.","volume":"116","author":"Elliott","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment.","volume":"18","author":"Feig","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.4161\/cbt.11.11.15534","article-title":"Inactivation of Brca2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.","volume":"11","author":"Feldmann","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051327","article-title":"Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models.","volume":"12","author":"Garcia","year":"2020","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006596","article-title":"Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer.","volume":"15","author":"Gendoo","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000745","article-title":"DNA damage response.","volume":"3","author":"Giglia-Mari","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_SUPPL.378","article-title":"Overall survival from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"39","author":"Golan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ijc.31292","article-title":"Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.","volume":"143","author":"Golan","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"40778","DOI":"10.18632\/oncotarget.17253","article-title":"Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.","volume":"8","author":"Golan","year":"2017","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1242\/dmm.021055","article-title":"GEMMs as preclinical models for testing pancreatic cancer therapies.","volume":"8","author":"Gopinathan","year":"2015","journal-title":"DMM Dis. Model. Mech."},{"key":"B34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4248\/IJOS11064","article-title":"DNA repair and synthetic lethality.","volume":"3","author":"Guo","year":"2011","journal-title":"Int. J. Oral Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.dnarep.2019.03.009","article-title":"The mismatch repair-dependent DNA damage response: Mechanisms and implications.","volume":"78","author":"Gupta","year":"2019","journal-title":"DNA Repair"},{"key":"B36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-016-0037-9","article-title":"Mechanisms of interstrand DNA crosslink repair and human disorders.","volume":"38","author":"Hashimoto","year":"2016","journal-title":"Genes Environ."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.4_suppl.637","article-title":"Randomized phase III study of FOLFOX alone and with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer (SEQUOIA).","volume":"38","author":"Hecht","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2144\/000112598","article-title":"The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?","volume":"43","author":"Hughes","year":"2007","journal-title":"Biotechniques"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer.","volume":"22","author":"Ilic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mc.20855","article-title":"Genetic susceptibility to pancreatic cancer.","volume":"51","author":"Klein","year":"2012","journal-title":"Mol. Carcinog."},{"key":"B44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00441-001-0510-y","article-title":"Establishment and characterization of four human pancreatic carcinoma cell lines: genetic alterations in the TGFBR2 gene but not in the MADH4 gene.","volume":"308","author":"Ku","year":"2002","journal-title":"Cell Tissue Res."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/srep33323","article-title":"WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.","volume":"6","author":"Lal","year":"2016","journal-title":"Sci. Rep."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3131-x","article-title":"A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.","volume":"17","author":"Laquente","year":"2017","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"14.39.1","DOI":"10.1002\/cpph.2","article-title":"Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-KrasG12D\/+;LSL-Trp53R172H\/+;Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery.","volume":"73","author":"Lee","year":"2016","journal-title":"Curr. Protoc. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236092","article-title":"DNA oxidation and excision repair pathways.","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/bjc.2015.220","article-title":"BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.","volume":"113","author":"Lohse","year":"2015","journal-title":"Br. J. Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167272","article-title":"Effects of combined treatment with ionizing radiation and the PARP inhibitor olaparib in BRCA mutant and wild type patient-derived pancreatic cancer xenografts.","volume":"11","author":"Lohse","year":"2016","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic.","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously-treated BRCA-mutated pancreas ductal adenocarcinoma.","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3727\/096504017X14926854178616","article-title":"The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways.","volume":"25","author":"Mini","year":"2017","journal-title":"Oncol. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4081\/oncol.2018.370","article-title":"Advanced pancreatic cancer: the standard of care and new opportunities.","volume":"12","author":"Mohammad","year":"2018","journal-title":"Oncol. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.3748\/wjg.v20.i28.9354","article-title":"Pancreatic cancer: advances in treatment.","volume":"20","author":"Mohammed","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.13.439717","article-title":"Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. Brief title: intratumoral heterogeneity of PDAC preclinical models.","author":"Monberg","year":"2021","journal-title":"bioRxiv"},{"key":"B58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcmgh.2017.12.004","article-title":"Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer.","volume":"5","author":"Moreira","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12051233","article-title":"Genetic alterations featuring biological models to tailor clinical management of pancreatic cancer patients.","volume":"12","author":"Nelson","year":"2020","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1016\/j.celrep.2017.11.003","article-title":"Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts.","volume":"21","author":"Nicolle","year":"2017","journal-title":"Cell Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/CNCR.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.","volume":"124","author":"O\u2019Reilly","year":"2018","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation.","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.21037\/jgo.2019.09.12","article-title":"DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.","volume":"10","author":"Palacio","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/1535-7163.MCT-17-0256","article-title":"Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.","volume":"19","author":"Park","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1080\/15384101.2018.1475827","article-title":"The contribution of DNA replication stress marked by high-intensity, pan-nuclear \u03b3H2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.","volume":"17","author":"Parsels","year":"2018","journal-title":"Cell Cycle"},{"key":"B66","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","article-title":"DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.","volume":"70","author":"Perkhofer","year":"2020","journal-title":"Gut"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage.","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90049-1","article-title":"Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.","volume":"11","author":"Pham","year":"2021","journal-title":"Sci. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","article-title":"A phase I\/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer.","volume":"26","author":"Pishvaian","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.molonc.2012.10.002","article-title":"Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.","volume":"7","author":"Porcelli","year":"2013","journal-title":"Mol. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features.","volume":"155","author":"Puleo","year":"2018","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","article-title":"Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes.","volume":"127","author":"Ranjha","year":"2018","journal-title":"Chromosoma"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092110","article-title":"Maintenance therapy for ATM-deficient pancreatic cancer by multiple DNA damage response interferences after platinum-based chemotherapy.","volume":"9","author":"Roger","year":"2020","journal-title":"Cells"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/j.gastro.2010.12.039","article-title":"Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.","volume":"140","author":"Rowley","year":"2011","journal-title":"Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8677","article-title":"Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.","volume":"6","author":"Russell","year":"2015","journal-title":"Nat. Commun."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes.","volume":"5","author":"Sch\u00e4rer","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX.","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/S41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles.","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.32662","article-title":"The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance.","volume":"146","author":"Shi","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B83","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccr.2010.10.015","article-title":"Germline Brca2 heterozygosity promotes KrasG12D -driven carcinogenesis in a murine model of familial pancreatic cancer.","volume":"18","author":"Skoulidis","year":"2010","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","article-title":"Advanced pancreatic carcinoma: current treatment and future challenges.","volume":"7","author":"Stathis","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells.","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"CellReports"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01443","article-title":"Upcoming revolutionary paths in preclinical modeling of pancreatic adenocarcinoma.","volume":"9","author":"Swayden","year":"2020","journal-title":"Front. Oncol."},{"key":"B87","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium.","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00956-5","article-title":"Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.","volume":"13","author":"Topatana","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1093\/annonc\/mdt280","article-title":"Family history of cancer and the risk of cancer: a network of case-control studies.","volume":"24","author":"Turati","year":"2013","journal-title":"Ann. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer.","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218273","article-title":"Targeting DNA damage response in prostate and breast cancer.","volume":"21","author":"Wengner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/abbs\/gmw046","article-title":"Non-homologous end joining: advances and frontiers.","volume":"48","author":"Yang","year":"2016","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","article-title":"A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.","volume":"101","author":"Yoo","year":"2009","journal-title":"Br. J. Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01787-5","article-title":"Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine.","volume":"40","author":"Yu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.606820","article-title":"Interpreting sequence variation in PDAC-predisposing genes using a multi-tier annotation approach performed at the gene, patient, and cohort level.","volume":"11","author":"Zimmermann","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.749490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:47:02Z","timestamp":1634147222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.749490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":98,"alternative-id":["10.3389\/fcell.2021.749490"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.749490","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"article-number":"749490"}}